JNJ stock forecast, quote, news & analysis

Key Takeaways

• Johnson & Johnson (JNJ) shares advanced roughly 7.7% over the trailing 30 days, climbing from about $256 to approximately $276 and trading near 52-week highs.
• The move was supported by third-quarter 2026 results that beat consensus estimates, with adjusted EPS of $2.59 and revenue near $25.4 billion, up about 6% year over year.
• Oncology remains the company's primary growth engine, led by Darzalex, Carvykti, Tecvayli, Rybrevant, Lazcluze, and Erleada, which helped offset Stelara's biosimilar-driven decline.
• Reported net income was sharply reduced by roughly $7 billion in one-time charges, primarily tied to the proposed $5.5 billion ovarian talc settlement, plus costs from the Firefly Bio acquisition and Sail Biomedicines collaboration.
• MedTech growth lagged at about 2.5%, pressured by electrophysiology competition and China pricing, though the OTTAVA robotic surgery authorization provides a new platform.
• Johnson & Johnson remains a Dividend King, having increased its dividend for 64 consecutive years, and declared a $1.34 per-share quarterly dividend in October 2026.
• Get more detail on this ticker's Price Targets, Earnings, and Forecast on dedicated pages.
• Explore Trending AI Robots to see AI-driven trading strategies across the market.

Current Market Snapshot

Johnson & Johnson shares have trended steadily higher over the trailing 30-day period, rising approximately 7.7% from a close near $256.48 in early October to roughly $276 by early November. The stock has been consolidating near multi-year and 52-week highs, reflecting investor confidence in the company's pivot toward higher-growth oncology and immunology franchises.

Broader sentiment toward the healthcare sector has remained constructive, with investors favoring large-cap pharmaceutical and medical device names that offer defensive cash flows, consistent dividends, and visible product pipelines. Johnson & Johnson's ability to raise full-year guidance even while absorbing a substantial litigation charge has reinforced its reputation as a resilient, diversified healthcare leader.

Johnson & Johnson (JNJ) Business Overview and Competitive Position

Johnson & Johnson is a global healthcare company operating across two primary segments: Innovative Medicine and MedTech. The Innovative Medicine business spans oncology, immunology, neuroscience, cardiovascular, and infectious disease therapies, while the MedTech segment includes surgical devices, orthopaedics, vision care, and cardiovascular technologies.

The company's competitive strengths include a diversified revenue base, a deep late-stage pipeline, a long track record of innovation, and substantial free cash flow that supports a 64-year streak of consecutive dividend increases. Oncology has emerged as the company's most important growth driver, with management stating an ambition to become the world's leading oncology company by the end of the decade. Investors follow JNJ closely as a bellwether for the healthcare industry, given its scale, global reach, and exposure to both pharmaceuticals and medical devices.

Recent Developments Driving JNJ

Several verified developments shaped Johnson & Johnson's performance over the trailing month. Third-quarter 2026 results, reported in mid-October, showed adjusted earnings and sales ahead of Wall Street expectations, and management raised full-year reported sales and adjusted earnings guidance. Oncology sales grew strongly across key medicines, with Darzalex, Carvykti, Tecvayli, and the Rybrevant/Lazcluze combination contributing notably.

At the same time, reported profit was depressed by approximately $7 billion in one-time charges, dominated by a proposed $5.5 billion resolution of long-running ovarian talc litigation. The settlement remains conditional on at least 95% of eligible claimants participating, leaving an element of uncertainty. Costs tied to the Firefly Bio acquisition and a Sail Biomedicines collaboration also weighed on the quarter.

In MedTech, growth was more modest, led by cardiovascular electrophysiology, contact lenses, and orthopaedic trauma, while pricing pressure in China and competition in electrophysiology acted as headwinds. A key positive was market authorization for OTTAVA, a table-integrated soft-tissue robotic surgery system that gives Johnson & Johnson a new competitive platform. Additionally, the company declared a quarterly dividend of $1.34 per share in October 2026, underscoring its commitment to shareholder returns.

Trending AI Robots

Tickeron's Trending AI Robots page offers a curated view of artificial intelligence-driven trading bots across a broad universe of stocks. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most relevant bots are featured in this section. Each bot operates with its own strategy, timeframe, and performance metrics, ranging from short-term momentum approaches to longer-horizon trend models. This makes the page a useful starting point for traders and investors interested in systematic, data-driven market analysis rather than discretionary judgment alone. Explore Trending AI Robots to review the currently featured strategies and see whether they align with your approach.

2026 Outlook and What Investors Should Watch

Looking ahead, several factors are likely to influence Johnson & Johnson shares through the remainder of 2026 and into 2027. The company's enterprise business review in December is expected to provide greater detail on its 2027 outlook, including how it plans to absorb the estimated $1.36 per-share earnings impact of recent deals. Investors will also monitor the final participation rate for the ovarian talc settlement, which requires at least 95% claimant opt-in to remain in force.

On the product front, potential U.S. approval of Rybrevant FASPRO in advanced head and neck cancer is expected before the end of 2026, while MedTech sales growth in the fiscal fourth-quarter report will be a closely watched metric after the segment fell short of management's own expectations. Ongoing risks include U.S. drug pricing reform, intense competition in immunology and oncology, and the execution of the planned separation of the orthopaedics business. Johnson & Johnson's ability to sustain oncology momentum while stabilizing MedTech and resolving litigation overhang will be central to its trajectory in the year ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations